Two widely touted Alzheimer’s drugs have been shown to enable patients to remain in their homes, living independently, for longer periods of time.Those medications, while effective, are not without their risks and side effects, however.That’s according to a recent study published last week in the Alzheimer’s Association journal.RED MEAT COULD RAISE DEMENTIA RISK, RESEARCHERS CLAIM, YET SOME DOCTORS HAVE QUESTIONSResearchers at Washington University School of Medicine in St. Louis analyzed how long 282 Alzheimer’s patients were able to continue living independently after taking two specific treatments: lecanemab (Leqembi) and donanemab (Kisunla).Both FDA-approved medications are designed to remove amyloid beta plaques
